Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETC-1922159 +/- Pembrolizumab in Advanced Solid Tumors
NCT02521844Phase 1Active, not recruiting
- Sponsor
- Experimental Drug Development Centre
- Start
- Oct 2015
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ETC-159 in solid tumor, colorectal cancer (CRC), ovarian cancer and 1 more (4 arms), sponsored by Experimental Drug Development Centre. Primary endpoints: Maximum Tolerated Dose at 42 days, Recommended Dose at 42 days and 7 more. Started Oct 2015; status: active, not recruiting.
02
Drugs
ETC-159
03
Conditions
solid tumorcolorectal cancer (CRC)ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT02521844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02521844.